Brit scientists find way to store vaccines in room temp

February 18th, 2010|

Scientists may have finally found a way to deal with one of developing world's worst problems in healthcare — faulty and inadequate cold chain for vaccine storage. British scientists from Oxford University have found a way to keep vaccines stable even in room temperature.

Biogen Idec lines up big India push

February 15th, 2010|

Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.

GSK inching closer to deal with Dr Reddys?

January 8th, 2010|

Citing people familiar with the matter, pharmaquest.biz reported that Glaxo will take a 20-per cent stake in Dr. Reddy's Holdings Ltd., a family vehicle that owns 23.2 per cent of the Hyderabad-based Dr Reddy's Laboratories.

Govt to examine Suns breast cancer drug

January 5th, 2010|

The government will examine Sun Pharma’s post marketing surveillance studies (PMS) and clinical trials report of breast cancer medicine Letrox (chemical name letrozole) to decide whether the drug should be banned from being marketed, as an anti-infertility drug among young women.

Year 2009: A period of inaction in policy matters relating to pharma healthcare

December 30th, 2009|

Yet another year has also gone by. But the issues related to pharma and health sectors remain mostly unresolved, thanks to the lackadaisical manner in which the government looks at these issues. Several crucial files regarding policies and regulations related to these sectors are still stuck at various government departments with no sign of immediate disposal. The only silver lining on the otherwise gloomy horizon was the introduction of 'Transplantation of Human Organs Act, 1994' in Parliament at the fag end of the last session of Parliament.

Cipla in talks to supply drugs to Germanys BI

December 15th, 2009|

German drugmaker Boehringer Ingelheim (BI) has started discussions with Cipla for a drug supply agreement that could see the Indian company supply generic drugs to the $17-billion German company for two of its drugs, including one of its best sellers. The Indian company is also discussing similar deals with other global pharma majors, said two persons familiar with the matter.

GSK to continue M&As in emerging markets

December 10th, 2009|

British drugmaker GlaxoSmithKline says it will pursue acquisitions in emerging markets, but expectations of family-owned companies are ‘unreasonable’ and the company would not pay such a price.

Ranbaxy exits Nihon JV, sells out to partner

December 8th, 2009|

Ranbaxy Laboratories on Tuesday said it was selling its 50 per cent stake in its Japanese joint venture Nihon Pharmaceutical Industry (NPI) to its partner Nippon Chemiphar.

Cipla in talks with global cos for research agreement

December 3rd, 2009|

Mumbai-based drugmaker Cipla is in talks with global pharma majors for a drug research and supply agreement, said a top company executive recently.

In healthcare, we can at best play catch-up with China

November 19th, 2009|

Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec, its therapy for a rare form of blood cancer called chronic myeloid leukemia, has spoken again on the alleged gaps in the Indian patent system.

India, the land of rising opportunities for Japan

November 2nd, 2009|

India has become a major hub for pharmaceutical companies of the world. An India-strategy is a must for all western companies and is often mandated by their managements.

Cadila Pharma eyes Rs 80 crore from Risorine

November 1st, 2009|

Aims to enter China, Russia and African countriesAhmedabad-based pharma major Cadila Pharmaceuticals is betting big on the latest product from its stable, Risorine, a combination drug for treating tuberculosis, as it plans to take the drug to markets like China, Russia and African countries in the long run and also expects to multiply its turnover from the segment by over ten times in the coming two years.

Dr Reddys net rises 106 percent on cost cuts, higher sales

October 23rd, 2009|

Dr Reddy’s Laboratories, India’s second-largest drug maker by sales after Ranbaxy, maintained its revenue growth forecast at 10% for this fiscal, despite pricing pressures in Germany and a shrinking pharma market in Russia.

EMPOWERING SMEs

October 13th, 2009|

Small and medium pharmaceutical companies are in a state of crisis. Their new set of problems started with the implementation of Good Manufacturing Practices as per the amended norms of Schedule M of the Drugs & Cosmetics Act in 2005.

IPA(MP) to organize seminar on enforcement and implications of Spurious Drugs Act

September 29th, 2009|

The Indian Pharmaceutical Association, Madhya Pradesh State Branch, Indore (IPA, MPSB) is organizing a one-day seminar on 'Drugs and Cosmetics (Amendment) Act, 2008: Enforcement, implications and provisions' on October 3 at Hotel Sayaji in Indore.

Lilly Reports on Outcome of Phase III Study of Arzoxifene

August 18th, 2009|

x (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

Can Emerging Markets Save Pharma?

August 2nd, 2009|

The emerging markets are the final frontier for pretty much every industry. The huge untapped markets have lots of potential, and pharmaceutical companies have jumped in full tilt.

Pharma companies looking to Womens Health for growth

July 29th, 2009|

During menopause, women experience many symptoms associated with the natural change in hormone levels. Hot flashes and sexual dysfunction are the most prevalent symptoms, and if untreated can lead to sleep deprivation and even depression.

Pharmaceutical Industry at Crossroads

July 7th, 2009|

To beat the financial crisis, experts say that many big pharmaceutical firms are seeking to collaborate or merge their businesses to better develop and market new blockbuster drugs.

Wockhardt sells German arm to Mova Pharma

June 17th, 2009|

Quick on the heels of a setback to divest its hospital chain to Apollo Hospitals, troubled Indian drugmaker, Wockhardt Ltd, which has debt of Rs3, 400 crore as on 31 December 2008, has succeeded in selling its German unit Esparma to Mova Pharma, the company announced yesterday.